Laurel A. Habel

15.0k total citations · 3 hit papers
200 papers, 9.9k citations indexed

About

Laurel A. Habel is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Laurel A. Habel has authored 200 papers receiving a total of 9.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 72 papers in Cancer Research and 48 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Laurel A. Habel's work include Breast Cancer Treatment Studies (51 papers), Global Cancer Incidence and Screening (38 papers) and Cancer Risks and Factors (33 papers). Laurel A. Habel is often cited by papers focused on Breast Cancer Treatment Studies (51 papers), Global Cancer Incidence and Screening (38 papers) and Cancer Risks and Factors (33 papers). Laurel A. Habel collaborates with scholars based in United States, Canada and United Kingdom. Laurel A. Habel's co-authors include Charles P. Quesenberry, Michaël Pollak, Judith G. Regensteiner, Michael C. Archer, Richard M. Bergenstal, Edward L. Giovannucci, David M. Harlan, Susan M. Gapstur, Douglas Yee and Theodore R. Levin and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Laurel A. Habel

195 papers receiving 9.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diabetes and Cancer

2010 1.8k citations Edward L. Giovannucci, David M. Harlan et al. Diabetes Care profile →
Diabetes and Cancer: A Consensus Report

2010 819 citations Edward L. Giovannucci, David M. Harlan et al. profile →
Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

2012 411 citations Erin J. Aiello Bowles, Heather Spencer Feigelson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurel A. Habel United States	47	3.7k	3.2k	2.6k	2.0k	1.8k	200	9.9k
Jonas Manjer Sweden	52	3.7k 1.0×	2.2k 0.7×	2.4k 0.9×	1.8k 0.9×	1.5k 0.8×	220	8.9k
Pamela J. Goodwin Canada	61	6.9k 1.9×	4.9k 1.5×	2.7k 1.0×	1.1k 0.6×	1.8k 1.0×	172	12.2k
Herbert Yu United States	62	3.6k 1.0×	6.0k 1.9×	3.6k 1.4×	889 0.4×	1.4k 0.8×	254	12.1k
Andrew G. Renehan United Kingdom	55	8.1k 2.2×	4.2k 1.3×	2.7k 1.0×	3.5k 1.7×	2.0k 1.1×	181	16.1k
Pär Stattin Sweden	74	5.0k 1.3×	4.9k 1.5×	3.6k 1.4×	2.1k 1.0×	7.0k 3.9×	419	16.8k
Peter H. Gann United States	45	2.0k 0.5×	2.4k 0.8×	1.8k 0.7×	811 0.4×	2.7k 1.5×	163	9.3k
Rudolf Kaaks Germany	70	6.2k 1.7×	4.9k 1.5×	3.2k 1.2×	1.3k 0.6×	2.0k 1.1×	308	18.2k
Mieke Van Hemelrijck United Kingdom	47	2.3k 0.6×	1.3k 0.4×	1.4k 0.5×	1.5k 0.7×	2.4k 1.3×	364	7.8k
Vincenzo Bagnardi Italy	60	5.0k 1.4×	2.1k 0.6×	2.8k 1.1×	2.3k 1.1×	2.2k 1.2×	302	14.2k
Heather Spencer Feigelson United States	35	2.0k 0.5×	1.5k 0.5×	970 0.4×	3.0k 1.5×	1.8k 1.0×	105	8.7k

Countries citing papers authored by Laurel A. Habel

Since Specialization

Citations

This map shows the geographic impact of Laurel A. Habel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurel A. Habel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurel A. Habel more than expected).

Fields of papers citing papers by Laurel A. Habel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurel A. Habel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurel A. Habel. The network helps show where Laurel A. Habel may publish in the future.

Co-authorship network of co-authors of Laurel A. Habel

This figure shows the co-authorship network connecting the top 25 collaborators of Laurel A. Habel. A scholar is included among the top collaborators of Laurel A. Habel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurel A. Habel. Laurel A. Habel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomas, Sachdev, Laurel A. Habel, Jennifer M. Suga, et al.. (2024). Evaluation of a predictive biomarker for antibody drug conjugates (ADCs).. Journal of Clinical Oncology. 42(16_suppl). 3140–3140. 1 indexed citations

Elkin, Eric P., Emily Valice, Laura B. Amsden, et al.. (2024). Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system. PLoS ONE. 19(6). e0303303–e0303303. 1 indexed citations

Lyon, Liisa, et al.. (2024). Abstract 3822: Oncotype DX testing and differences in use of chemotherapy by age in an integrated system. Cancer Research. 84(6_Supplement). 3822–3822.

Pan, Minggui, Chen Jiang, Zheyang Zhang, et al.. (2023). Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies. Cancers. 15(10). 2665–2665. 9 indexed citations

Baker, Robin J., Sally Agersborg, Thomas K. Lee, et al.. (2023). Evaluation of the international Ki67 working group cut point recommendations for early breast cancer: comparison with 21-gene assay results in a large integrated health care system. Breast Cancer Research and Treatment. 203(2). 281–289. 2 indexed citations

Kristensen, Kasper Bruun, Søren Friis, Lars Christian Lund, et al.. (2022). Identification of Drug–Cancer Associations: A Nationwide Screening Study. Cancer Research Communications. 2(6). 552–560. 2 indexed citations

Solomon, Daniel H., Kristine Ruppert, Laurel A. Habel, et al.. (2021). Prescription medications for sleep disturbances among midlife women during 2 years of follow-up: a SWAN retrospective cohort study. BMJ Open. 11(5). e045074–e045074. 4 indexed citations

Emerson, Marc A., Ninah Achacoso, Halei C. Benefield, Melissa A. Troester, & Laurel A. Habel. (2021). Initiation and adherence to adjuvant endocrine therapy among urban, insured American Indian/Alaska Native breast cancer survivors. Cancer. 127(11). 1847–1856. 12 indexed citations

Habel, Laurel A., Ninah Achacoso, Bruce Fireman, Sidsel Arnspang Pedersen, & Anton Pottegård. (2021). Hydrochlorothiazide and risk of melanoma subtypes. Pharmacoepidemiology and Drug Safety. 30(10). 1396–1401. 9 indexed citations

10.

Sieh, Weiva, Joseph H. Rothstein, Robert J. Klein, et al.. (2020). Identification of 31 loci for mammographic density phenotypes and their associations with breast cancer risk. Nature Communications. 11(1). 5116–5116. 23 indexed citations

11.

Alexeeff, Stacey, Jafi A. Lipson, Ninah Achacoso, et al.. (2017). Age at Menarche and Late Adolescent Adiposity Associated with Mammographic Density on Processed Digital Mammograms in 24,840 Women. Cancer Epidemiology Biomarkers & Prevention. 26(9). 1450–1458. 18 indexed citations

12.

Jones, Lee W., Marilyn L. Kwan, Erin Weltzien, et al.. (2016). Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies. Cancer Research. 76(18). 5415–5422. 42 indexed citations

13.

Arem, Hannah, Louise A. Brinton, Steven C. Moore, et al.. (2015). Physical Activity and Risk of Male Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 24(12). 1898–1901. 2 indexed citations

14.

Sakoda, Lori C., Assiamira Ferrara, Ninah Achacoso, et al.. (2015). Metformin Use and Lung Cancer Risk in Patients with Diabetes. Cancer Prevention Research. 8(2). 174–179. 34 indexed citations

15.

Habel, Laurel A., G. Thomas Ray, Michael J. Silverberg, et al.. (2012). The Epidemiology of Herpes Zoster in Patients with Newly Diagnosed Cancer. Cancer Epidemiology Biomarkers & Prevention. 22(1). 82–90. 80 indexed citations

16.

Livaudais, Jennifer C., Andrea Z. LaCroix, Rowan T. Chlebowski, et al.. (2012). Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative. Cancer Epidemiology Biomarkers & Prevention. 22(3). 365–373. 23 indexed citations

17.

Goddard, Katrina A.B., Erin J. Aiello Bowles, Heather Spencer Feigelson, et al.. (2012). Utilization of HER2 genetic testing in a multi-institutional observational study.. PubMed. 18(11). 704–12. 12 indexed citations

18.

Giovannucci, Edward L., David M. Harlan, Michael C. Archer, et al.. (2010). Diabetes and Cancer. Diabetes Care. 33(7). 1674–1685. 1753 indexed citations breakdown →

19.

Baehner, Frederick L., Ninah Achacoso, Tara Maddala, et al.. (2010). Human Epidermal Growth Factor Receptor 2 Assessment in a Case-Control Study: Comparison of Fluorescence In Situ Hybridization and Quantitative Reverse Transcription Polymerase Chain Reaction Performed by Central Laboratories. Journal of Clinical Oncology. 28(28). 4300–4306. 91 indexed citations

20.

Habel, Laurel A., et al.. (2005). Treatment with Stimulants among Youths in a Large California Health Plan. Journal of Child and Adolescent Psychopharmacology. 15(1). 62–67. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact